ClinicalTrials.gg
CompletedNCT00874237Updated Apr 22, 2026Results posted

Staccato Loxapine Thorough QT/QTc Study

A Phase 1 interventional study of Inhaled loxapine and Inhaled placebo in Thorough QT/QTc Study, sponsored by Nova Pneuma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Nova Pneuma Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of the present Phase 1 study was to assess the cardiac safety of Staccato Loxapine administered to healthy volunteers in a 3 period crossover study.

Read the detailed description

Primary Objective: To assess the maximum effect of Staccato Loxapine on cardiac repolarization (QTc interval duration) at the anticipated maximum clinical dose compared to placebo in healthy volunteers.

Secondary Objective: To assess the QTc versus loxapine concentration relationship following treatment with Staccato Loxapine in healthy volunteers.

02

Conditions studied

  • Thorough QT/QTc Study

Keywords

  • Staccato loxapine
  • QT/QTc
  • healthy volunteers
  • Thorough QT/QTc study
  • ADASUVE
  • inhaled loxapine
03

In context

Lead sponsor

Nova Pneuma Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are in good general health and agree to use a medically acceptable and effective method throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have taken prescription or nonprescription medication within 5 days of treatment,
  • Subjects who have had an acute illness within the last 5 days of treatment,
  • Subjects who are smokers, OR
  • Subjects who have an abnormality at baseline.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Other
    Treatment sequence ABC

    Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg

    Drug: Inhaled loxapine · Drug: Inhaled placebo · Drug: Oral moxifloxacin · Drug: Oral placebo

  • Other
    Treatment sequence ACB

    Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg

    Drug: Inhaled loxapine · Drug: Inhaled placebo · Drug: Oral moxifloxacin · Drug: Oral placebo

  • Other
    Treatment sequence BCA

    Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg

    Drug: Inhaled loxapine · Drug: Inhaled placebo · Drug: Oral moxifloxacin · Drug: Oral placebo

  • Other
    Treatment sequence BAC

    Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg

    Drug: Inhaled loxapine · Drug: Inhaled placebo · Drug: Oral moxifloxacin · Drug: Oral placebo

  • Other
    Treatment sequence CAB

    Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg

    Drug: Inhaled loxapine · Drug: Inhaled placebo · Drug: Oral moxifloxacin · Drug: Oral placebo

  • Other
    Treatment sequence CBA

    Treatment: A = Inhaled loxapine 10 mg, B = Placebo, C = Oral moxifloxacin 400 mg

    Drug: Inhaled loxapine · Drug: Inhaled placebo · Drug: Oral moxifloxacin · Drug: Oral placebo

Interventions

  • DrugLoxapineStudies of LoxapineLoxapine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Inhaled Staccato Loxapine 10 mg single dose

    Also known as: ADASUVE

  • DrugInhaled placebo

    Inhaled Staccato placebo single dose

  • DrugMoxifloxacinStudies of MoxifloxacinMoxifloxacin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral moxifloxacin 400 mg

  • DrugOral placebo

    Oral placebo similar in appearance to moxifloxacin 400 mg

06

What researchers measure

Primary outcomes

  1. Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo

    Largest of the upper CIs of the time matched differences in QTcI values between the maximum of the mean difference from baseline of the QTcI interval after time matched placebo subtraction for ADASUVE treatment at 12 prespecified post inhalation times

    Time frame: 1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours

Secondary outcomes

  1. Cardiac Repolarization Change (QTcI) Versus Loxapine Concentration Relationship Following Treatment With Staccato Loxapine in Healthy Volunteers.

    QTcI change at the median loxapine concentration (32.2 mcg/mL) based on nonlinear regression of QTcI versus log of time matched serum loxapine concentrations. This analysis looks for repolarization versus concentration relationship in a positive or negative thorough QT/QTc study result.

    Time frame: 24 hours

  2. Numbers and % of Subjects With QTcI > 450 ms

    Numbers and Percents of Subjects with QTcI exceeding 450 ms

    Time frame: 1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours

  3. Numbers and % of Subjects With QTcI > 480 ms

    Numbers and Percents of Subjects with QTcI exceeding 480 ms

    Time frame: 1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours

  4. Numbers and % of Subjects With QTcI Change > 30 ms

    Numbers and Percents of Subjects with QTcI increase from baseline exceeding 30 ms

    Time frame: 1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours

  5. Numbers and % of Subjects With QTcI Change > 60 ms

    Numbers and Percents of Subjects with QTcI increase from baseline exceeding 60 ms

    Time frame: 1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours

Other outcomes

  1. Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)

    A thorough QT/QTc study may be considered to have demonstrated assay sensitivity if 1 or more of the lower 95% CI values exceeds 5 msec ant any of the 9 predetermined time points

    Time frame: 1, 1.5, 2, 2.5, 3, 5, 8, 12, and 24 hr

07

Results

Posted Oct 30, 2019
Limitations and caveats
The highest approved inhaled loxapine dose of 10 mg was studied. Supratherapeutic doses were not evaluated because of tolerability concerns in healthy subjects. The inclusion of only healthy subjects is likewise a limitation of this study.

Participant flow

132 subjects were screened.

Participant flow — Overall Study
MilestoneTreatment Sequence ABCTreatment Sequence ACBTreatment Sequence BCATreatment Sequence BACTreatment Sequence CABTreatment Sequence CBA
Started888888
Completed877888
Not completed011000
Withdrew: Physician decision010000
Withdrew: Withdrawal by subject001000

Outcome measures

PrimaryMaximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo

Largest of the upper CIs of the time matched differences in QTcI values between the maximum of the mean difference from baseline of the QTcI interval after time matched placebo subtraction for ADASUVE treatment at 12 prespecified post inhalation times

Time frame:
1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours
Reported as:
Least squares mean · mseconds
Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo
msecondsInhaled Loxapine 10 mg vs Placebo Crossover Subjects
Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo5.418 (3.083 to 7.753)
SecondaryCardiac Repolarization Change (QTcI) Versus Loxapine Concentration Relationship Following Treatment With Staccato Loxapine in Healthy Volunteers.

QTcI change at the median loxapine concentration (32.2 mcg/mL) based on nonlinear regression of QTcI versus log of time matched serum loxapine concentrations. This analysis looks for repolarization versus concentration relationship in a positive or negative thorough QT/QTc study result.

Time frame:
24 hours
Reported as:
Least squares mean · mseconds
Cardiac Repolarization Change (QTcI) Versus Loxapine Concentration Relationship Following Treatment With Staccato Loxapine in Healthy Volunteers.
msecondsInhaled Loxapine 10 mg
Cardiac Repolarization Change (QTcI) Versus Loxapine Concentration Relationship Following Treatment With Staccato Loxapine in Healthy Volunteers.4.238 (2.859 to 5.617)
SecondaryNumbers and % of Subjects With QTcI > 450 ms

Numbers and Percents of Subjects with QTcI exceeding 450 ms

Time frame:
1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours
Reported as:
Count of participants · Participants
Numbers and % of Subjects With QTcI > 450 ms
ParticipantsInhaled Loxapine 10 mgInhaled Placebo
Numbers and % of Subjects With QTcI > 450 ms11
SecondaryNumbers and % of Subjects With QTcI > 480 ms

Numbers and Percents of Subjects with QTcI exceeding 480 ms

Time frame:
1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours
Reported as:
Count of participants · Participants
Numbers and % of Subjects With QTcI > 480 ms
ParticipantsInhaled Loxapine 10 mgInhaled Placebo
Numbers and % of Subjects With QTcI > 480 ms00
SecondaryNumbers and % of Subjects With QTcI Change > 30 ms

Numbers and Percents of Subjects with QTcI increase from baseline exceeding 30 ms

Time frame:
1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours
Reported as:
Count of participants · Participants
Numbers and % of Subjects With QTcI Change > 30 ms
ParticipantsInhaled Loxapine 10 mgInhaled Placebo
Numbers and % of Subjects With QTcI Change > 30 ms11
SecondaryNumbers and % of Subjects With QTcI Change > 60 ms

Numbers and Percents of Subjects with QTcI increase from baseline exceeding 60 ms

Time frame:
1, 2, 5, 9, 15, 30 min, 1, 3, 6, 10 and 23 hours
Reported as:
Count of participants · Participants
Numbers and % of Subjects With QTcI Change > 60 ms
ParticipantsInhaled Loxapine 10 mgInhaled Placebo
Numbers and % of Subjects With QTcI Change > 60 ms00
Other pre-specifiedMaximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)

A thorough QT/QTc study may be considered to have demonstrated assay sensitivity if 1 or more of the lower 95% CI values exceeds 5 msec ant any of the 9 predetermined time points

Time frame:
1, 1.5, 2, 2.5, 3, 5, 8, 12, and 24 hr
Reported as:
Least squares mean · mseconds
Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)
msecondsOral Moxifloxacin vs Placebo Crossover Subjects
Maximum Effect of Moxifloxacin on Cardiac Repolarization (QTc Interval Duration) Compared to Placebo (Study Assay Sensitivity)8.356 (5.825 to 10.877)

Adverse events

Collected over Adverse events (AEs) were considered treatment related from the first exposure to study treatment until 30 days after the last treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Inhaled Loxapine 10 mg0/47 (0%)0/47 (0%)38/47 (80.9%)
Placebo0/47 (0%)0/47 (0%)19/47 (40.4%)
Oral Moxifloxacin0/47 (0%)0/47 (0%)9/47 (19.1%)
Most frequent other events
Most frequent other events
EventInhaled Loxapine 10 mgPlaceboOral Moxifloxacin
SomnolenceNervous system disorders29/477/472/47
DizzinessNervous system disorders17/472/474/47
DysgeusiaGastrointestinal disorders9/471/472/47
CoughRespiratory, thoracic and mediastinal disorders7/472/471/47
HeadacheNervous system disorders2/474/472/47
Dermatitis, contactSkin and subcutaneous tissue disorders3/473/470/47

Baseline characteristics

Safety population

Age, Categorical
Age, Categorical(Participants)All Subjects Treated
<=18 years0
Between 18 and 65 years48
>=65 years0
Age, Continuous
Age, Continuous(years)All Subjects Treated
Mean40.854 ± 13.481
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects Treated
Female24
Male24
Region of Enrollment
Region of Enrollment(participants)All Subjects Treated
United States47
08

Study locations

1 site
  • Covance Clinical Research Unit Inc.
    Evansville, Indiana 47710, United States
09

References and documents

Publications

  • Spyker DA, Voloshko P, Heyman ER, Cassella JV. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. J Clin Pharmacol. 2014 Jun;54(6):665-74. doi: 10.1002/jcph.257. Epub 2014 Jan 22. PubMed 24375070 ↗

Individual participant data

Plan to share: Yes — IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsDoc@alexza.com

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 10 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2009
First posted
Apr 2, 2009
Start
Apr 2009
Primary completionActual
Jun 2009
CompletionActual
Jun 2009
Results first posted
Oct 30, 2019
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00874237
Lead sponsor
Nova Pneuma Inc.
Collaborators
Covance
Responsible party
Sponsor
First posted
Apr 2, 2009
Start date
Apr 2009
Primary completion
Jun 2009
Completion
Jun 2009
Results posted
Oct 30, 2019
Last update
Apr 22, 2026

Study contacts

Randall R. Stoltz, MD
principal investigator · Covance

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Loxapine

Start the discussion